Biogen Shares Are Trading Higher After Partner Eisai Initiated the Rolling Submission of a BLA for Lecanemab-irmb for Subcutaneous Autoinjector for Weekly Maintenance Dosing.
Biogen Shares Are Trading Higher After Partner Eisai Initiated the Rolling Submission of a BLA for Lecanemab-irmb for Subcutaneous Autoinjector for Weekly Maintenance Dosing.
在合作伙伴衛材開始滾動提交用於每週維持劑量的LeCanemab-IRMB皮下自動注射器的BLA後，Biogen股價走高。
Biogen Shares Are Trading Higher After Partner Eisai Initiated the Rolling Submission of a BLA for Lecanemab-irmb for Subcutaneous Autoinjector for Weekly Maintenance Dosing.
在合作伙伴衛材開始滾動提交用於每週維持劑量的LeCanemab-IRMB皮下自動注射器的BLA後，Biogen股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。